## **UCSF UC San Francisco Previously Published Works**

### **Title**

CNTF Induces Regeneration of Cone Outer Segments in a Rat Model of Retinal Degeneration

### **Permalink**

<https://escholarship.org/uc/item/79p6v2kz>

## **Journal**

PLOS ONE, 5(3)

## **ISSN**

1932-6203

### **Authors**

Li, Yiwen Tao, Weng Luo, Lingyu [et al.](https://escholarship.org/uc/item/79p6v2kz#author)

# **Publication Date**

2010

### **DOI**

10.1371/journal.pone.0009495

Peer reviewed

## CNTF Induces Regeneration of Cone Outer Segments in a Rat Model of Retinal Degeneration

### Yiwen Li<sup>1</sup>, Weng Tao<sup>2</sup>, Lingyu Luo<sup>1</sup>, Deqiang Huang<sup>1</sup>, Konrad Kauper<sup>2</sup>, Paul Stabila<sup>2</sup>, Matthew M. LaVail<sup>3</sup>, Alan M. Laties<sup>4</sup>, Rong Wen<sup>1</sup>\*

1 Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, Florida, United States of America, 2 Neurotech USA, Lincoln, Rhode Island, United States of America, 3 Beckman Vision Center, University of California San Francisco, San Francisco, California, United States of America, 4 Department of Ophthalmology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

#### Abstract

Background: Cone photoreceptors are responsible for color and central vision. In the late stage of retinitis pigmentosa and in geographic atrophy associated with age-related macular degeneration, cone degeneration eventually causes loss of central vision. In the present work, we investigated cone degeneration secondary to rod loss in the S334ter-3 transgenic rats carrying the rhodopsin mutation S334ter.

Methodology/Principal Findings: Recombinant human ciliary neurotrophic factor (CNTF) was delivered by intravitreal injection to the left eye of an animal, and vehicle to the right eye. Eyes were harvested 10 days after injection. Cone outer segments (COS), and cell bodies were identified by staining with peanut agglutinin and cone arrestin antibodies in wholemount retinas. For long-term treatment with CNTF, CNTF secreting microdevices were implanted into the left eyes at postnatal day (PD) 20 and control devices into the right eyes. Cone ERG was recorded at PD 160 from implanted animals. Our results demonstrate that an early sign of cone degeneration is the loss of COS, which concentrated in many small areas throughout the retina and is progressive with age. Treatment with CNTF induces regeneration of COS and thus reverses the degeneration process in early stages of cone degeneration. Sustained delivery of CNTF prevents cones from degeneration and helps them to maintain COS and light-sensing function.

Conclusions/Significance: Loss of COS is an early sign of secondary cone degeneration whereas cell death occurs much later. At early stages, degenerating cones are capable of regenerating outer segments, indicating the reversal of the degenerative process. Sustained delivery of CNTF preserves cone cells and their function. Long-term treatment with CNTF starting at early stages of degeneration could be a viable strategy for preservation of central vision for patients with retinal degenerations.

Citation: Li Y, Tao W, Luo L, Huang D, Kauper K, et al. (2010) CNTF Induces Regeneration of Cone Outer Segments in a Rat Model of Retinal Degeneration. PLoS ONE 5(3): e9495. doi:10.1371/journal.pone.0009495

Editor: Xiao-Jiang Li, Emory University, United States of America

Received January 18, 2010; Accepted February 12, 2010; Published March 2, 2010

Copyright: © 2010 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by National Institutes of Health (NIH) grants R01EY015289 (RW), R01EY001919 (MML), R01EY0006842 (MML), Hope for Vision (RW), a grant from the James and Esther King Biomedical Research Program of the State of Florida (YL) and a grant from the Department of Defense (USAMRMC NO: 08192003, RW). It was also supported by NIH Core Grants P30EY14801 and P30EY002162, the Foundation Fighting Blindness (MML), and unrestricted grants from Research to Prevent Blindness Inc. to Bascom Palmer Eye Institute and Beckman Vision Center. The above funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Neurotech USA supplied the CNTF intraocular implants for this study. Neurotech USA is developing CNTF intraocular implants. As some of the authors are employed by Neurotech USA, this company had a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Weng Tao, Konrad Kauper, and Paul Stabila are employees of Neurotech USA. Alan M. Laties and Rong Wen are consultants of Neurotech USA. Matthew M. LaVail is a co-inventor of US patent US5667968, which covers CNTF treatments for retinal degenerations and other retinopathies. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

E-mail: rwen@med.miami.edu

#### Introduction

Retinal degenerations are a major cause of blindness for which no effective treatments are available [1]. It is estimated that one in 3,500 to 4,000 people are affected by retinitis pigmentosa (RP), a heterogeneous group of inherited retinal degenerative disorders. Mutations in at least 34 genes are identified to be responsible for RP [1]. Most mutations responsible for the RP phenotype selectively affect rod photoreceptors, nevertheless cones undergo degeneration secondary to the loss of rods, often leading to total blindness [1,2]. How to save the cones has become a major research challenge.

A number of neurotrophic factors have demonstrated neuroprotective effects in mitigating retinal degenerations [3]. Among them, (CNTF ciliary neurotrophic factor) has shown a promising capability to inhibit progression of retinal degenerations in a variety of animal models, as well as in light-induced damage [4– 12]. CNTF, initially identified as a factor in chick embryo extract that supported viability of embryonic chick ciliary neurons [13,14] and later purified to homogeneity [15,16], exhibits multiple biological effects in the retina. CNTF promotes the survival and axonal regeneration of retinal ganglion cells [17–20] and acts as neuronal differentiation factor, promotes the differentiation of a subclass of cone photoreceptors expressing green opsin in the

PLoS one

developing chick retina [21–23], enhances the expression of bipolar neuron markers in rat retinal cultures [24–26], and inhibits rod photoreceptor cell differentiation [22,25–27], and promotes Müller glia genesis from the postnatal retinal progenitor pool [28]. It has been reported that CNTF regulates the phototransduction machinery of rod photoreceptors, and the regulation was mediated through Müller cells  $[29,30]$ .

In the present study, we investigated the secondary degeneration of cones in transgenic rats carrying the rhodopsin mutation S334ter, a model of retinal degeneration. In this model, rod photoreceptors undergo rapid degeneration soon after birth [31]. Cone degeneration starts at the peak of rod degeneration, and is characterized by loss of COS in many round or irregularly shaped areas across the retina. When treated with CNTF, cones are stimulated to regenerate their COS. These results provide evidence that in early stages, CNTF reverses secondary cone degeneration. In addition, our results show that sustained delivery of CNTF helps cones to maintain COS and their functions.

#### Results

#### Loss of COS in Early Stages of Cone Degeneration

The degeneration rate of homozygous S334ter-3 rats (Fig. 1) is quite similar to that observed in the heterozygous animals [31]. Pyknotic nuclei are readily seen by postnatal day (PD) 10. Massive rod photoreceptor death occurs between PD 12 to PD 16. By PD 20, most of the rod photoreceptors are degenerated. Only one incomplete row of photoreceptor nuclei remains in the outer nuclear layer (ONL) where photoreceptor cell nuclei reside. By PD 30 and PD 60, even fewer nuclei remain and all appear to be cone nuclei. In contrast, no significant photoreceptor loss occurs in wildtype rats from PD 8 to PD 60 (Fig. 2). To investigate the distribution of COS, we used PNA to identify



Figure 1. Photoreceptor degeneration in homozygous S334ter-3 rats. Plastic-embedded sections of retinas from S334ter-3 rats of PD 8 (A), 10 (B), 12 (C), 14 (D), 16 (E), 18 (F), 20 (G), 30 (H), and 60 (I) were examined by light microscopy (superior regions). The outer nuclear layer (ONL) is indicated in each panel by a white vertical bar. Pyknotic nuclei are indicated by white arrowheads (B). Loss of photoreceptors was progressive and by PD 20 most of rod photoreceptors were degenerated, and the ONL had less than a complete row of nuclei. Sections were stained with toluidine blue. Scale bar, 20  $\mu$ m. doi:10.1371/journal.pone.0009495.g001



Figure 2. Photoreceptors in Sprague-Dawley rats. Plasticembedded sections of retinas from wild-type Sprague-Dawley rats of PD 8 (A), 12 (B), 16 (C), 20 (D), 30 (E), and 60 (F) were examined by light microscopy (superior regions). The ONL is indicated in each panel by a white vertical bar. No progressive loss of photoreceptors is observed. Sections were stained with toluidine blue. Scale bar, 20 um. doi:10.1371/journal.pone.0009495.g002

COS in whole-mounted retinas. PNA specifically binds to the cone photoreceptor extracellular matrix and stains COS [32,33]. At PD 10, PNA staining is evenly distributed across the entire retina (Fig. 3A). Loss of PNA staining first is detected at PD12 when rod degeneration is at its peak (data not shown). By PD 20, many small round or irregularly shaped PNA-negative areas were observed, indicating focal loss of COS (Fig. 3B). The PNA staining outside the PNA-negative areas is similar to the retina of PD 10. The loss of PNA staining progresses with age (Fig. 3A–3F), as demonstrated clearly in the quantitative analysis of COS densities (Fig. 3J). In comparison, PNA staining in wild-type animals was distributed evenly without any PNA-negative area (Fig. 3G–3I).

To confirm the specificity of PNA staining of COS, we performed double-staining experiments with PNA and antibodies against red/green or blue opsin (Fig. 4). The distribution of red/ green (Fig. 4A) or blue opsin (Fig. 4B) immunostaining overlaps very well with PNA staining. The specificity of PNA staining of COS is clearly shown at higher magnification in figure 4C in which a cone photoreceptor was double-stained with PNA and antibodies against blue opsin. PNA labeled almost exclusively the outer segment (Fig. 4C), whereas antibodies against blue opsin stained not only the outer segment, but also, to a lesser degree, the inner segment, the cell body, and the synaptic terminal (Fig. 4C).

We next stained cones using antibodies against cone arrestin (CAR), which specifically stained cone cells from the synaptic terminals to the outer segment [34]. At PD 20, many CARpositive cells were found inside PNA-negative areas (Fig. 5A), identifying them cones without COS. By PD 90, however, only a few CAR-positive cells remained in the PNA-negative areas (Fig. 5B). Thus, by PD 90, most of the cones in the PNA-negative areas were degenerated. Staining in retinal sections showed that at



COS/0.13 mm<sup>2</sup> 1000 800 600 400 200  $\overline{0}$ 10 20 30 60 90 180 Age (postnatal days)

Figure 3. Loss of COS in the retinas of S334ter-3 rats. Wholemounted retinas (superior regions) of S334ter-3 rats (Tg) are shown at PD 10 (A), 20 (B), 30 (C), 60 (D), 90 (E), and 180 (F), as well as retinas of wild-type (Wt) rats at PD10 (G), 20 (H), and 60 (I). Retinas were stained with PNA and examined by confocoal microscopy. In S334ter-3 retinas, loss of PNA staining is concentrated in small round or irregularly shaped areas. The loss of PNA staining was progressive with age (A–F). Quantitative analysis of the density of PNA positive cells in the S334-ter-3 retinas clearly shows the progressive loss of PNA positive cells in the superior retina (J, mean  $\pm$  SD, n = 4). No such loss of PNA positive cells was found in wild-type retinas (G-I). Scale bar: 200  $\mu$ m. doi:10.1371/journal.pone.0009495.g003

PD 20, PNA labeling was interrupted by PNA-negative gaps (Fig. 5C, between two arrows), corresponding to the PNA-negative areas found in whole-mounted retinas. Many CAR-positive cells were found inside the PNA-negative gaps (Fig. 5C), consistent with data from whole-mounted retinas.

In addition, data from retinal sections provided evidence that PNA-negative areas in the whole-mounted retinas were not an artifact that might have been resulted from uneven separation of the retina from the RPE during tissue preparation. In a retinal detachment created during tissue preparation, the retina was negative of PNA staining, and so was the overlaying RPE (Fig. 5C, arrowheads). If the PNA-negative areas were an artifact of uneven tissue separation, the RPE side would have been PNA positive.



Figure 4. Specificity of PNA staining to COS. Whole-mounted retinas (superior regions) of S334ter-3 rats (PD 30) were double stained with PNA and antibodies against red/green opsin (A) or blue opsin (B). PNA-staining overlaps with red/green opsin or blue opsin staining very well. The specificity of PNA staining to COS was confirmed under high magnification (C). PNA stained almost exclusively COS (C), whereas antibodies against blue opsin stained not only COS, but also, to a lesser degree, the inner segment, the cell body, and the synaptic terminal (C). Scale bar: 50  $\mu$ m for A and B; 10  $\mu$ m for C. doi:10.1371/journal.pone.0009495.g004

This finding is consistent with results from additional experiments in which both the retinas and the RPE-choroid preparations were stained with PNA, but no PNA staining was detected in the RPEchoroid preparations (data not shown).

#### CNTF Promotes COS Regeneration

To investigate the effects of CNTF on cone photoreceptors, retinas were treated with CNTF and examined 10 days later. When treated with CNTF at PD 10 (endpoint PD 20), PNA staining was evenly distributed without obvious PNA-negative areas (Fig. 6A), whereas in PBS-treated fellow eyes, many PNAnegative areas appeared (Fig. 6D). When treated between the ages of PD 20 to PD 50 (endpoints PD 30 to PD 60), the PNA-negative areas became much smaller and in most cases completely disappeared (Fig. 6B and 6C). In contrast, many PNA-negative areas were found in the PBS-treated fellow retinas (Fig. 6E and 6F). The CNTF induced increase in PNA staining became less dramatic at PD 80 (endpoint PD 90, Fig. 6G) and almost no such increase was seen in retinas of PD 170 (endpoint PD 180, Fig. 6H), similar to PBS treated fellow retinas (Fig. 6I and 6J, respectively).

The increase in PNA-positive cells in PD 20 and PD 30 retinas treated with CNTF (Fig. 6B and 6C) indicates that CNTF treatment not only stopped further degeneration, but also induced reappearance of PNA staining, suggesting regeneration of COS. To confirm this observation, eyes were treated with CNTF at PD 35 and retinas were examined at PD 45 for PNA-positive cells. Indeed, the density of PNA-positive cells in CNTF treated retinas of PD 45 (Fig. 7C) was more than that in the retina of PD 35 (Fig. 7A) before the treatment. Quantitative analyses showed that the density of PNA-positive cells in CNTF treated retinas of PD 45 was significantly more than in the PD 35 controls when the treatment started (Fig. 7D). These results provide evidence that



Figure 5. Loss of COS and cone cells. Whole-mounted retinas (superior regions) of S334ter-3 rats were double stained with PNA and antibodies against cone arrestin (CAR). In the retina of PD 20 (A), many CAR positive cells were found in the PNA-negative areas. In the retina of PD 90 (B), however, only a few CAR-positive cells remained in the PNAnegative areas. Cryosections of a PD 20 retina (C) double stained with PNA and antibodies against CAR showed a gap of PNA staining corresponding to a negative area seen in whole-mounted retinas (C, between two arrows). CAR positive cells were found in the gap. The retina detachment (arrowhead) showed that in the PNA-negative area (between two arrows), the corresponding RPE side is also negative. Retinal layers were indicated in C with white vertical bars. PE: RPE; ONL: outer nuclear layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL, ganglion cell layer. Scale bars: 100  $\mu$ m for A and B; 50  $\mu$ m for C. doi:10.1371/journal.pone.0009495.g005

CNTF treatment can promote regeneration of COS in degenerating cones.

#### Long-Term Effect of CNTF on Cones

Long-term delivery of CNTF to the retina was achieved by using CNTF-secreting microdevices [35–37]. Animals were implanted with CNTF devices in the left eyes and control devices in the right eyes at PD 20. Eyes were collected at PD160, 140 days after implantation. Both PNA- and red/green-opsin-positive cells in the CNTF treated retinas (Fig. 8A and 6B, respectively) were significantly more than those in the control retinas of the fellow eyes (Fig. 8C and 8D, respectively). Quantitative analysis shows that density of PNA-positive or red/green opsin-positive cells in CNTF treated retinas is significantly more than in the control retinas (Fig. 8E).

In another experiment, preservation of cone function was assessed by ERG recording. At PD 30, rats were implanted with CNTF-secreting devices in the left eyes and devices containing the parental cells as controls in the right eyes. Cone ERGs were recorded at PD 135. The cone b-wave amplitude in CNTF-treated eyes is significantly larger than in control eyes (Fig. 8F and 8G). Thus, sustained delivery of CNTF helps to preserve the function of cones as well.

#### **Discussion**

The present study demonstrates that the secondary cone degeneration starts with loss of COS as an early sign, whereas



Figure 6. Increase in PNA-positive cells after CNTF treatment. Retinas (superior regions) of PD 10, 20, 50, 80, and 170 S334ter-3 rats were treated with either CNTF (left eyes) or PBS (right eyes) and collected 10 days after treatment. Whole-mounted retinas of PD 20 (i.e., injected at PD 10; A, CNTF; D, PBS), PD 30 (B, CNTF; E, PBS), PD 60 (C, CNTF; F, PBS), PD 90 (G, CNTF; I, PBS), and PD 180 (H, CNTF; J, PBS), were stained with PNA. Many PNA-negative areas appeared in PBS treated retinas, whereas no PNA-negative areas were seen in the PD 20 retinas treated with CNTF (A). The PNA-negative areas became much smaller and in most cases completely disappeared in PD 30 and 60 retinas treated with CNTF (B and C). Increase in PNA positive cells after CNTF treatment became less dramatic in PD 60 retinas (G), and by PD 180 (H), little or no significant increase is observed. Scale bar: 200  $\mu$ m. doi:10.1371/journal.pone.0009495.g006

the actual cell death occurs much later. In the early stages of degeneration, cones without COS are not only alive and but are capable of regenerating their outer segments, indicating that at this time the degeneration process is reversible. Sustained delivery of CNTF preserves cone cells and their function.

The delay between loss of COS and cell death is likely in the time frame of about two months in this model. This is based on the finding that loss of COS is readily observable at PD 20; that retinas of S334ter-3 rats lack of CAR-positive cells in the PNA-negative areas at PD 90 (Fig. 3); and that the CNTF-induced regeneration of COS was dramatically decreased at PD 80 (Fig. 4). The twomonth window is rather large considering the rapid rod degeneration (about 10 days) in these animals. Thus, secondary cone degeneration is a relatively slow process, which not only provides an opportunity to study the pathology of secondary cone degeneration, but also serves a model for pre-clinical assessment of potential treatments. Furthermore, this finding raises the possibility that a similar window may exist in patients with RP. Because of the slow progression of degeneration in RP patients, this delay in



Figure 7. Regeneration of COS induced by CNTF treatment. Retinas (superior regions) of S334ter-3 rats at PD 35 were treated with either CNTF or PBS and harvested 10 days after treatment. Wholemounted retinas of PD 35 (A, before treatment), PD 45 treated with PBS at PD 35 (B), and PD 45 treated with CNTF at PD 35 (C) were stained with PNA. PNA positive cells in CNTF treated retinas are more than those in either PBS treated retinas or PD 35 retinas. Quantitative analysis showed that PNA-positive cells are significantly more in the PD 45 CNTF treated retinas (657 $\pm$ 76, n = 4) than in the PD 35 retinas (467 $\pm$ 73, n = 3), or PD 45 retinas treated with PBS (334 $\pm$ 33, n = 3) (D, mean  $\pm$  SD), indicating regeneration of COS in response to CNTF treatment. Asterisk indicates  $P<0.05$ ; double-asterisk indicates  $P \le 0.01$  (ANOVA analysis and Bonferroni test). Scale bar: 100 µm. doi:10.1371/journal.pone.0009495.g007

patients could be very long, which would provide a large window to allow therapeutic intervention to save cones.

The observation that CNTF stimulated regeneration of COS demonstrates that in the early stages of degeneration, cones are capable of regenerating COS under favorable circumstances and thus the degeneration is reversible. Obviously, this finding has strong clinical significance. COS are functional organelles that initiate the conversion of photons to neuronal signals. Without COS, cones lose their light-sensing function. Regeneration of COS therefore means that in the early stages of degeneration, cones may restore their light sensing capabilities and thus restore vision. In light of this finding, we may want to re-think current therapeutic strategies for RP. At present, the goal of RP treatment is to slow down or stop the degeneration. Instead, we perhaps want to think more about restoring and maintaining useful vision. It is possible that in RP patients, many degenerating cones retain the capability of regenerating COS. If that is the case, it may be possible to promote regeneration of COS and thus restore vision to some extent for those patients. Consistent with this notion is a recent finding in a Phase I clinical trial using CNTF for retinal degenerations, in which one patient with late-stage RP had a significant improvement of vision [38].

CNTF is a neurotrophic factor that has been shown consistently to protect rod photoreceptor from degeneration [4–12]. Our present study demonstrates that sustained delivery of CNTF helps



Figure 8. Long-term effects of sustained delivery of CNTF. Eyes of S334ter-3 rats were implanted with microdevices containing CNTFsecreting cells or parental cells at PD 20 and harvested on PD 160. Whole-mounted retinas (superior regions) were stained with PNA or antibodies against red/green opsin. PNA or red/green opsin positive cells are more in the retinas treated with CNTF devices (A and B than the fellow control retinas (C and D). Quantitative analysis of PNA or red/ green positive cells in the superior retina showed significantly more cells in CNTF-treated retinas (446 $\pm$ 80 and 310 $\pm$ 46, respectively) than the controls (141 $\pm$ 40 and 108 $\pm$ 46, respectively) (E, mean  $\pm$  SD, n = 3). Cone ERGs were recorded at PD 135 from eyes implanted at PD 20 with CNTF secreting or control devices. Representative b-waves from CNTF treated and control eyes are shown in panel F. The onset of flash is indicated by an arrowhead. The amplitudes of b-waves from CNTF treated retinas (32.46 $\pm$ 10.02 µV) is significantly larger than from control retinas (17.70 $\pm$ 4.78 µV) (G, mean  $\pm$  SD, n = 3). Asterisk indicates P<0.05; double-asterisk indicates P<0.01 (Student t-test). Scale bar: 50 mm.

doi:10.1371/journal.pone.0009495.g008

cones to preserve COS and cone function for an extended period. These findings provide experimental evidence to support longterm sustained delivery of neurotrophic factors such as CNTF as a treatment strategy to benefit RP patients by preserving cone function and useful vision.

The exact cause of secondary cone degeneration is not clear, although a number of hypotheses have been proposed, as reviewed by Delyfer and co-worker [2]. These include the secondary loss of cones due to 1) toxic byproducts of dying rod photoreceptors; 2) the loss of structural support by the loss of rods; 3) remodeling as evidenced by new and abnormal synaptic connections after rod degeneration; 4) changes in the RPE and Müller cells due to rod degeneration; and 5) the loss of rod-derived cone viability factors (RdCVFs) that are produced by rods and are thought to support cone survival; loss of rods leads to loss of RdCVFs [39]. In addition to these possibilities, activation of microglia during rod cell loss could be a factor [40,41]. Oxidative stress is also believed to cause secondary cone degeneration: the loss of rods leads to exposure to a relatively oxygen-rich environment that is detrimental to cones [42–45]. Yet another potential mechanism of cone cell degeneration following rod loss is prolonged starvation due to nutrient deprivation in cones [46]. While it is unclear whether one or more of these mechanisms results in secondary cone cell death, the problem is further complicated by the findings in the present study of the S334ter-3 rat suggesting that there are two geographically separated populations of cones in terms of their susceptibility to the degenerative pressure(s). One population includes cones in the PNA-negative areas, which are more susceptible to the degeneration pressure(s), and the other population that is less susceptible in the PNA-positive areas. The geographic distribution of cones must now be taken into consideration when studying cellular mechanisms of cone cell death.

Taken together, the present study demonstrated that an early sign of cones degeneration is the loss of COS. CNTF promotes regeneration of COS and protects cone from further degeneration. Long-term treatment with CNTF starting at an early stage of degeneration could be a viable strategy for preservation of vision for RP patients.

#### Materials and Methods

#### Ethics Statement

All procedures involving animals adhered to Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Institutional Animal Care and Use Committee of University of Miami, Miller School of Medicine.

#### Animals and Intravitreal Injections

Homozygous transgenic rats (Sprague-Dawley background) carrying a murine rhodopsin mutant S334ter (line3) and wildtype Sprague-Dawley (Harlan Laboratories, Indianapolis, IN) rats were used in all experiments. The rate of photoreceptor degeneration in the homozygotes was similar to that observed in heterozygous animals [31]. Intravitreal injections were delivered through 33-gauge needles connected to 10-µl microsyringes (Hamilton, Reno, NV), as described previously [29]. One eye (left) of an animal was injected with recombinant human CNTF protein and the other with phosphate buffered saline (PBS). Eyes were collected 10 days after injection.

#### Recombinant CNTF Protein

Expression and purification of recombinant CNTF protein were as previously described [29]. The open reading frame of human CNTF cDNA was cloned into an expression vector pQE30 (Qiagen, Valencia, CA) to generate plasmid pQE-CNTF. Recombinant human CNTF protein was expressed in E. coli (XL-blue, Stratagene, La Jolla, CA) and purified by immobilizedmetal affinity chromatography on Ni-NTA Agarose columns (Qiagen, Valencia, CA) under native conditions. Eluted protein was buffer-exchanged to phosphate buffered saline (PBS). Purified protein was stored at  $-80^{\circ}$ C.

#### Implantation of CNTF Secreting Microdevices

CNTF secreting microdevices, provided by Neurotech USA (Lincoln, RI), were microtubes of  $1.5 \text{ mm} \times 0.5 \text{ mm}$  in size, small enough for implanting into rat eyes. The wall of the microtubes was made of 90–100  $\mu$ m thick semi-permeable hollow-fiber membrane. CNTF-secreting cells were encapsulated in the devices using the Encapsulated Cell Technology (ECT) [35–37]. The devices used in the experiments had a mean CNTF output of 0.8 ng/24 hr in culture. Control devices had parental cells with no CNTF-secreting capability.

For long-term studies, microdevices were implanted in the vitreous at postnatal day (PD) 20. To implant a microdevice, the sclera on the temporal side was exposed and an incision was made between the limbus and equator with a sharp #28 needle to reach the vitreous. A microdevice was put into the vitreous through the insertion at a  $45^\circ$  angle toward the posterior pole. The position of an implanted microdevice was confirmed visually through the pupil.

#### Tissue Preparation and Immunohistochemistry

For whole-mounted retinas, animals were killed by  $CO<sub>2</sub>$ inhalation and perfused with PBS. Eyecups were prepared by removing the cornea along the limbus and then the iris. Retinalens preparations were obtained by first making a small cut at the edge of sclera toward the posterior pole. Then with a pair of forceps at each side of the cut, the sclera, along with the choroid and RPE (retinal pigment epithelium), was carefully torn open, and the sclera-choroid-RPE was peered off from the retina-lens to the base of optic nerve. The sclera-choroid-RPE was then cut off from the base of optic nerve. The resulted retina-lens preparations were post-fixed in cold 4% paraformaldehyde solution for 4 hours at  $4^{\circ}C$ .

For retinal cryo-sections, animals were killed by  $CO<sub>2</sub>$  inhalation and perfused with PBS then 4% paraformaldehyde. Eyes were collected and the corneas and lenses were removed. The resulted eyecups were fixed in 4% paraformadehyde in 0.1 M phosphate buffer for 4 hrs and then equilibrated in 30% sucrose in 0.1 M phosphate buffer overnight at  $4^{\circ}$ C. Retinal sections (16 µm) were cut on a cryostat at  $-20^{\circ}$ C, mounted on Super Frost Plus Gold slides (Fisher Scientific, Pittsburgh, PA), and air dried overnight at room temperature (RT).

Peanut agglutinin (PNA) was used to identify COS. For PNA staining, retina-lens preparations were incubated with FITCconjugated (Vector, Burlingame, CA) or Alexa fluor 488-conjugate (Invitrogen) PNA. The lenses were removed and the retinas were flat-mounted on slides.

For immunostaining, retina-lens preparations or cryo-sections were incubated with anti-red/green opsin; anti-blue opsin (Santa Cruz Biotechnology); or anti-mouse cone arrestin (LUMIJ, a gift of Dr. Cheryl Craft of the University of Southern California), and visualized with Alexa Fluor 594 anti-goat IgG (Invitrogen, Carlsbad, CA) or Cy3 conjugated anti-rabbit antibody (Jackson immunoresearch lab, West grove, PA). For double-staining with PNA, Alexa fluor 488-conjugate PNA was added to the secondary antibody solution. All samples were examined by confocal microscopy.

#### Quantification of PNA-Positive Cells

Confocal images from whole mount of retina were used to calculate the cone cell density (PNA or red/green opsin positive cells) in the superior retinas using software Volocity (Improvision, Waltham, MA). Data were expressed as mean $\pm$ S.D.

#### ERG Recording

Cone ERGs were recorded with a UTAS system (LKC Technologies, Gaithersburg, MD). Under Animals were anesthetized with intraperitoneal ketamine (80 mg/kg) and xylazine (4 mg/kg). Pupils were dilated with 0.1% atropine and 0.1% phenylephrine HCl. During the recording, animals were maintained at 35°C on a heated plate. A contact lens electrode with a platinum wire was placed on the cornea, a differential electrode under the skin of the forehead, and a ground wire electrode was placed under the skin close to the base of the tail. Both eyes were recorded simultaneously. Photopic ERG responses were elicited by 1 ms white flashes of 2.5 log  $\text{cd·s/m}^2$ generated by white LEDs in the Ganzfeld sphere of the UTAS system, with low white background illumination (30  $cd·s/m<sup>2</sup>$ ). Inter-stimulus intervals were 10 s. Each recording was an average of 10 responses.

#### Statistic Analysis

Statistic analyses were performed using InStat (version 3.0, GraphPad Software Inc., San Diego, CA). Results were evaluated by ANOVA or Student's t-test for comparisons between experimental groups.

#### References

- 1. Hartong DT, Berson EL, Dryja TP (2006) Retinitis pigmentosa. Lancet 368: 1795–1809.
- 2. Delyfer MN, Leveillard T, Mohand-Said S, Hicks D, Picaud S, et al. (2004) Inherited retinal degenerations: therapeutic prospects. Biol Cell 96: 261–269.
- 3. Wenzel A, Grimm C, Samardzija M, Reme CE (2005) Molecular mechanisms of light-induced photoreceptor apoptosis and neuroprotection for retinal degeneration. Progress in retinal and eye research 24: 275–306.
- 4. Cayouette M, Gravel C (1997) Adenovirus-mediated gene transfer of ciliary neurotrophic factor can prevent photoreceptor degeneration in the retinal degeneration (rd) mouse. Hum Gene Ther 8: 423–430.
- 5. Cayouette M, Behn D, Sendtner M, Lachapelle P, Gravel C (1998) Intraocular gene transfer of ciliary neurotrophic factor prevents death and increases responsiveness of rod photoreceptors in the retinal degeneration slow mouse. J Neurosci 18: 9282–9293.
- 6. LaVail MM, Yasumura D, Matthes MT, Lau-Villacorta C, Unoki K, et al. (1998) Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci 39: 592–602.
- 7. Chong NH, Alexander RA, Waters L, Barnett KC, Bird AC, et al. (1999) Repeated injections of a ciliary neurotrophic factor analogue leading to longterm photoreceptor survival in hereditary retinal degeneration. Invest Ophthalmol Vis Sci 40: 1298–1305.
- 8. Caffe AR, Soderpalm AK, Holmqvist I, van Veen T (2001) A combination of CNTF and BDNF rescues rd photoreceptors but changes rod differentiation in the presence of RPE in retinal explants. Invest Ophthalmol Vis Sci 42: 275–282.
- 9. Liang FQ, Aleman TS, Dejneka NS, Dudus L, Fisher KJ, et al. (2001) Longterm protection of retinal structure but not function using RAAV.CNTF in animal models of retinitis pigmentosa. Mol Ther 4: 461–472.
- 10. Bok D, Yasumura D, Matthes MT, Ruiz A, Duncan JL, et al. (2002) Effects of adeno-associated virus-vectored ciliary neurotrophic factor on retinal structure and function in mice with a P216L rds/peripherin mutation. Exp Eye Res 74: 719–735.
- 11. Tao W, Wen R, Goddard MB, Sherman SD, O'Rourke PJ, et al. (2002) Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 43: 3292–3298.
- 12. LaVail MM, Unoki K, Yasumura D, Matthes MT, Yancopoulos GD, et al. (1992) Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc Natl Acad Sci U S A 89: 11249–11253.
- 13. Adler R, Landa KB, Manthorpe M, Varon S (1979) Cholinergic neuronotrophic factors: intraocular distribution of trophic activity for ciliary neurons. Science 204: 1434–1436.
- 14. Varon S, Manthorpe M, Adler R (1979) Cholinergic neuronotrophic factors: I. Survival, neurite outgrowth and choline acetyltransferase activity in monolayer cultures from chick embryo ciliary ganglia. Brain Res 173: 29–45.
- 15. Lin LF, Mismer D, Lile JD, Armes LG, Butler ET, 3rd, et al. (1989) Purification, cloning, and expression of ciliary neurotrophic factor (CNTF). Science 246: 1023–1025.
- 16. Stockli KA, Lottspeich F, Sendtner M, Masiakowski P, Carroll P, et al. (1989) Molecular cloning, expression and regional distribution of rat ciliary neurotrophic factor. Nature 342: 920–923.
- 17. Weise J, Isenmann S, Klocker N, Kugler S, Hirsch S, et al. (2000) Adenovirusmediated expression of ciliary neurotrophic factor (CNTF) rescues axotomized rat retinal ganglion cells but does not support axonal regeneration in vivo. Neurobiol Dis 7: 212–223.
- 18. Jo SA, Wang E, Benowitz LI (1999) Ciliary neurotrophic factor is and axogenesis factor for retinal ganglion cells. Neuroscience 89: 579–591.
- 19. Cui Q, Lu Q, So KF, Yip HK (1999) CNTF, not other trophic factors, promotes axonal regeneration of axotomized retinal ganglion cells in adult hamsters. Invest Ophthalmol Vis Sci 40: 760–766.
- 20. Meyer-Franke A, Kaplan MR, Pfrieger FW, Barres BA (1995) Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron 15: 805–819.
- 21. Fuhrmann S, Kirsch M, Hofmann HD (1995) Ciliary neurotrophic factor promotes chick photoreceptor development in vitro. Development 121: 2695–2706.
- 22. Kirsch M, Fuhrmann S, Wiese A, Hofmann HD (1996) CNTF exerts opposite effects on in vitro development of rat and chick photoreceptors. Neuroreport 7: 697–700.
- 23. Xie HQ, Adler R (2000) Green cone opsin and rhodopsin regulation by CNTF and staurosporine in cultured chick photoreceptors. Invest Ophthalmol Vis Sci 41: 4317–4323.

#### Acknowledgments

We thank Dr. Cheryl Craft for anti cone-arrestin antibodies; Dr. Ying Song, Dr. Lian Zhao, and Yun Liu for technical assistance.

#### Author Contributions

Conceived and designed the experiments: YL WT ML AL RW. Performed the experiments: YL LL DH KK PS RW. Analyzed the data: YL WT LL DH KK PS ML RW. Wrote the paper: YL WT ML AL RW.

- 24. Bhattacharya S, Dooley C, Soto F, Madson J, Das AV, et al. (2004) Involvement of Ath3 in CNTF-mediated differentiation of the late retinal progenitors. Mol Cell Neurosci 27: 32–43.
- 25. Ezzeddine ZD, Yang X, DeChiara T, Yancopoulos G, Cepko CL (1997) Postmitotic cells fated to become rod photoreceptors can be respecified by CNTF treatment of the retina. Development 124: 1055–1067.
- 26. Schulz-Key S, Hofmann HD, Beisenherz-Huss C, Barbisch C, Kirsch M (2002) Ciliary neurotrophic factor as a transient negative regulator of rod development in rat retina. Invest Ophthalmol Vis Sci 43: 3099–3108.
- 27. Neophytou C, Vernallis AB, Smith A, Raff MC (1997) Muller-cell-derived leukaemia inhibitory factor arrests rod photoreceptor differentiation at a postmitotic pre-rod stage of development. Development 124: 2345–2354.
- 28. Goureau O, Rhee KD, Yang XJ (2004) Ciliary neurotrophic factor promotes muller glia differentiation from the postnatal retinal progenitor pool. Dev Neurosci 26: 359–370.
- 29. Wen R, Song Y, Kjellstrom S, Tanikawa A, Liu Y, et al. (2006) Regulation of rod phototransduction machinery by ciliary neurotrophic factor. J Neurosci 26: 13523–13530.
- 30. Wen R, Song Y, Liu Y, Li Y, Zhao L, et al. (2008) CNTF negatively regulates the phototransduction machinery in rod photoreceptors: implication for lightinduced photostasis plasticity. Advances in experimental medicine and biology 613: 407–413.
- 31. Liu C, Li Y, Peng M, Laties AM, Wen R (1999) Activation of caspase-3 in the retina of transgenic rats with the rhodopsin mutation s334ter during photoreceptor degeneration. J Neurosci 19: 4778–4785.
- 32. Blanks JC, Johnson LV (1983) Selective lectin binding of the developing mouse retina. J Comp Neurol 221: 31–41.
- 33. Hageman GS, Johnson LV (1986) Biochemical characterization of the major peanut-agglutinin-binding glycoproteins in vertebrate retinae. J Comp Neurol 249: 499–510, 482–493.
- 34. Zhu X, Li A, Brown B, Weiss ER, Osawa S, et al. (2002) Mouse cone arrestin expression pattern: light induced translocation in cone photoreceptors. Mol Vis 8: 462–471.
- 35. Tao W (2006) Application of encapsulated cell technology for retinal degenerative diseases. Expert opinion on biological therapy 6: 717–726.
- 36. Tao W, Wen R (2007) Application of encapsulated cell technology for retinal degenerative diseases. In: Retinal Degenerations: Biology, Diagnostics, and Therapeutics. Tombran-Tink J, Barnstable CJ eds. The Humana Press.
- 37. Tao W, Wen R, Aguirre GD, Laties AM (2006) Cell-Based delivery systems: development of encapsulated cell technology for ophthalmic applications. ;In: Intraocular drug delivery: principles and clinical applications. Jaffe GJ, Ashton P eds. Taylor & Francis.
- 38. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, et al. (2006) Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 103: 3896–3901.
- 39. Leveillard T, Mohand-Said S, Lorentz O, Hicks D, Fintz AC, et al. (2004) Identification and characterization of rod-derived cone viability factor. Nat Genet 36: 755–759.
- 40. Gupta N, Brown KE, Milam AH (2003) Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration. Exp Eye Res 76: 463–471.
- 41. Langmann T (2007) Microglia activation in retinal degeneration. Journal of leukocyte biology 81: 1345–1351.
- 42. Chrysostomou V, Valter K, Stone J (2009) Cone-rod dependence in the rat retina: variation with the rate of rod damage. Invest Ophthalmol Vis Sci 50: 3017–3023.
- 43. Komeima K, Rogers BS, Lu L, Campochiaro PA (2006) Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natl Acad Sci U S A 103: 11300–11305.
- 44. Shen J, Yang X, Dong A, Petters RM, Peng YW, et al. (2005) Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa. Journal of cellular physiology 203: 457–464.
- 45. Stone J, Maslim J, Valter-Kocsi K, Mervin K, Bowers F, et al. (1999) Mechanisms of photoreceptor death and survival in mammalian retina. Progress in retinal and eye research 18: 689–735.
- 46. Punzo C, Kornacker K, Cepko CL (2009) Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. Nature neuroscience 12: 44–52.